Global Pharmaceuticals & Biotech Mid-Large Cap Stocks

Ultragenyx Pharmaceutical

Market Cap: US$2.9b

A biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific.

Dyne Therapeutics

Market Cap: US$1.8b

A clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States.

Verona Pharma

Market Cap: US$9.2b

A biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs.

Inner Mongolia Furui Medical Science

Market Cap: CN¥19.7b

Inner Mongolia Furui Medical Science Co., Ltd.

Avidity Biosciences

Market Cap: US$6.2b

A biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs).

ApicHope Pharmaceutical Group

Market Cap: CN¥26.7b

Engages in the research and development, production, and sale of pharmaceutical drugs.

Amneal Pharmaceuticals

Market Cap: US$3.3b

A global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.

MannKind

Market Cap: US$1.7b

A biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States.

GuangYuYuan Chinese Herbal Medicine

Market Cap: CN¥9.3b

GuangYuYuan Chinese Herbal Medicine Co., Ltd.

Sotera Health

Market Cap: US$4.6b

Provides sterilization, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally.

Alvotech

Market Cap: US$2.6b

Through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide.

Protagonist Therapeutics

Market Cap: US$4.0b

A biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases.

Immunovant

Market Cap: US$2.8b

A clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases.

Ocular Therapeutix

Market Cap: US$1.9b

A biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States.

Shenzhen Chipscreen Biosciences

Market Cap: CN¥13.1b

Shenzhen Chipscreen Biosciences Co., Ltd.

Tonghua Golden-Horse Pharmaceutical Industry CoLtd

Market Cap: CN¥24.7b

Engages in the research, development, manufacture, and sale of pharmaceutical products in China.

Regencell Bioscience Holdings

Market Cap: US$7.8b

Operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong.

Zai Lab

Market Cap: US$3.8b

A biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases.

10x Genomics

Market Cap: US$1.5b

A life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific.

Crinetics Pharmaceuticals

Market Cap: US$3.9b

A clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.

Walvax Biotechnology

Market Cap: CN¥18.6b

Engages in the research and development, manufacture, and distribution of vaccines in China.

Nuvalent

Market Cap: US$6.0b

A clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer.

Aurinia Pharmaceuticals

Market Cap: US$1.5b

A biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs.

Alkermes

Market Cap: US$5.1b

A biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.

Natera

Market Cap: US$22.2b

A diagnostics company, provides molecular testing services worldwide.

Edgewise Therapeutics

Market Cap: US$1.6b

A biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders.

Charles River Laboratories International

Market Cap: US$8.4b

Charles River Laboratories International, Inc.

Harrow

Market Cap: US$1.8b

An eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products.

Legend Biotech

Market Cap: US$6.0b

Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.

Joinn Laboratories(China)Co.Ltd

Market Cap: CN¥24.4b

Provides preclinical and non-clinical services in the United States, the People’s Republic of China, and internationally.

Agios Pharmaceuticals

Market Cap: US$2.3b

A biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States.

Twist Bioscience

Market Cap: US$1.8b

Manufactures and sells synthetic DNA-based products.

Biohaven

Market Cap: US$1.6b

Biohaven Ltd. discovers, develops, and commercializes therapies for immunology, neuroscience, and oncology worldwide.

AbCellera Biologics

Market Cap: US$1.8b

Engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.

ORIC Pharmaceuticals

Market Cap: US$1.1b

A clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms cancers in the United States.

Kymera Therapeutics

Market Cap: US$3.9b

A clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system.